Zacks Reaffirms Neutral Rating on Catalyst Health Solutions (CHSI)
Catalyst Health Solutions opened at 85.75 on Monday. Catalyst Health Solutions has a 52-week low of $45.35 and a 52-week high of $92.62. The company has a market cap of $3.857 billion and a price-to-earnings ratio of 63.99.
Catalyst Health Solutions last posted its quarterly earnings results on Thursday, May 3rd. The company reported $0.62 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.59 by $0.03. Catalyst Health Solutions’s revenue was up 29.7% compared to the same quarter last year. Analysts expect that Catalyst Health Solutions will post $0.69 EPS next quarter.
A number of other firms have also recently commented on CHSI. Analysts at BMO Capital Markets downgraded shares of Catalyst Health Solutions from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, April 23rd. Separately, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Catalyst Health Solutions from $68.00 to $100.00 in a research note to investors on Thursday, April 19th. They now have a “buy” rating on the stock. Finally, analysts at Maxim Group downgraded shares of Catalyst Health Solutions from a “buy” rating to a “hold” rating in a research note to investors on Thursday, April 19th.
Catalyst Health Solutions, Inc. is a full-service pharmacy benefit management (PBM) company. The Company operates under the brand name Catalyst Rx.